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Regulatory T Cells: Minireview
Key Controllers of
Immunologic Self-Tolerance
selection are further subjected to control in the periph-
ery; T cells can be rendered anergic (i.e., functionally
inactivated without death) or deleted upon encounter
with self-antigens in the periphery. In addition to these
ªpassiveº mechanisms of controlling self-reactive T
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cells, there appears to be a ªdominantº control mecha-Japan
nismÐcertain T cells actively downregulate the activa-
tion/proliferation of self-reactive T cells. The existence
of such regulatory (or suppressor) T cells has been aOur immune system protects us from a myriad of poten-
great controversy among immunologists and has beentially pathogenic microorganisms while avoiding re-
given little credibility for many years, largely because ofacting with constituents of our body; i.e., we are tolerant
the paucity of reliable markers for defining the cell, theof ªself.º Failure of immunologic self-tolerance often
ambiguity in the molecular basis of suppressive phe-leads to the development of autoimmune disease, which
nomena, and even the elusive nature of some sup-is estimated to afflict up to 5% of the population. Al-
pressive phenomena themselves. Nevertheless, if onethough the etiology of autoimmune disease is at present
asks which mechanism of self-tolerance should, whenlargely unknown, it is well documented that T cells are
it goes awry, directly lead to autoimmune disease orthe key mediators of many autoimmune diseases, such
which one, when strengthened, can prevent autoim-as insulin-dependent diabetes mellitus (IDDM), autoim-
mune disease, accumulating experimental evidencemune thyroiditis, and autoimmune gastritis accompa-
now suggests that removal or inactivation of a certainnying pernicious anemia. Furthermore, there is mounting
regulatory T cell population can break natural self-toler-evidence that normal healthy individuals harbor poten-
ance, leading to spontaneous development of varioustially pathogenic self-reactive T cells. For example, im-
autoimmune diseases. Studies on transplantation toler-munization of normal animals with a self-antigen in po-
ance have also documented that T cells actively inhibittent adjuvant can induce dormant self-reactive T cells to
effector T cells from rejecting grafts in a certain tolerantattack the antigen, eliciting inflammatory tissue damage.
state. Furthermore, recent advances in cytokine re-
Self-reactive T cell clones can also easily be isolated
search have revealed that T cells secreting immunosup-
from the peripheral blood of normal healthy individuals
pressive cytokines behave as regulatory T cells and in-
by repeated in vitro stimulation with self-molecules.
deed downregulate autoimmunity and responses to
Moreover, many tumor-associated antigens recognized
transplants. This review will discuss recent advances in
by autologous T cells in cancer patients have now turned our understanding of the key role of regulatory T cells
out to be normal self-constituents, not abnormal prod- in immunologic tolerance.
ucts of mutated genes, indicating that tumor immunity Self-Tolerance Is Maintained by CD41
is in part an autoimmunity. One of the current key issues Regulatory T Cells
in immunology is therefore to elucidate how potentially The existence of regulatory T cells with autoimmune-
hazardous (or sometimes beneficial) self-reactive T cells inhibitory activity has been suggested in various animal
are generated in physiological or disease states, and models of autoimmune disease since the early 1980s
how they are regulated to avoid autoimmune disease (references cited in Itoh et al., 1999). For example, in
(or not to attack autologous tumor cells). A better under- NOD (non-obese diabetic) mice or BB (Bio-Breeding)
standing of the mechanisms underlying immunologic rats, which spontaneously develop IDDM and autoim-
tolerance will lead to better treatments for autoimmune mune thyroiditis, inoculation with CD41 T cells from
disease, cancer, and transplant rejection. histocompatible normal animals effectively prevented
During T cell maturation in the thymus, immature T IDDM. On the other hand, characterization of effector T
cells express an enormously diverse range of T cell cells mediating these organ-specific autoimmune dis-
antigen receptors (TCRs) formed by random rearrange- eases has firmly documented that CD41 helper T cells
ments of TCR a and b chain gene segments, but only cause the damage by helping B cells to form autoanti-
T cells expressing TCRs that recognize major histocom- bodies and by inducing cell-mediated immune re-
patibility complex (MHC) and associated self-peptides sponses to self-antigens. Recent experiments with
with moderate affinity can differentiate (positive selec- transgenic mice that harbor CD41 T cells expressing
tion). T cells whose TCRs fail to bind the MHC/self- transgenic TCRs reacting with self-antigens, such as
peptide complex and T cells expressing TCRs that bind myelin basic proteins (one of the target self-antigens
the complex too strongly are subjected to programmed in multiple sclerosis in humans), have also shown that
cell death (death by neglect and negative selection, re- inoculation of normal CD41 T cells can prevent the auto-
spectively). However, thymic negative selection does immunity (Olivares-Villagomez et al., 1998; Van de Keere
and Tonegawa, 1998). These findings, when taken to-not seem to be sufficient to control self-reactive T cells
gether, suggest that normal individuals may harbor twoand thereby prevent autoimmune disease. Self-reactive
functionally distinct populations of CD41 T cells, oneT cells that have somehow escaped thymic negative
capable of mediating autoimmune disease and the other
dominantly inhibiting it, and that the interactions be-
tween the two populations, the latter being dominant* E-mail: shimon@frontier.kyoto-u.ac.jp
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Figure 1. Induction of Autoimmune Diseases in T Cell±Deficient
Mice (or Rats) by Transferring CD41 T Cell Suspensions Eliminated
of a Particular Subpopulation Defined by the Expression Levels of
Various Cell Surface Molecules
Figure 2. Immunologic Self-Tolerance Maintained by CD41 Regula-See text for details.
tory T Cells
See text for details. M`, macrophages.in the physiological state, can be a key mechanism in
maintaining self-tolerance. To test this hypothesis di-
and the periphery, may directly lead to spontaneousrectly, attempts have been made from the mid 1980s to
activation/expansion of self-reactive T cells and conse-dissect the normal CD41 T cell population into smaller
quently to the development of various autoimmune dis-subpopulations by expression levels of a particular cell
eases (Itoh et al., 1999) (Figure 2).surface molecule and to examine the potential correla-
In organ transplantation, tolerance can often be adop-tion of the separation with autoimmune induction or
tively transferred by lymphocytes from long-term survi-inhibition (Sakaguchi et al., 1985; Itoh et al., 1999; and
vors to naive recipients (Zhai and Kupiec-Weglinski,references therein). The cell surface molecules that have
1999; and references therein). For example, allograftbeen employed to date are CD25 (the interleukin [IL]-2
tolerance can be established by a short course of admin-receptor a chain generally expressed on activated T
istering cyclosporin A, a T cell±specific immunosuppres-cells), CD45RB/RC (a protein tyrosine phosphatase ex-
sant, or monoclonal antibody blocking the CD4 moleculepressed in almost all hematopoetic cells), CD5 (ex-
(or other molecules on the T cell surface) at the time ofpressed at high levels on mature T cells and a possible
grafting; and this tolerance can be transferred to naiveligand for CD72), and RT6.1 (expressed on the majority
animals by CD41 T cells from tolerant donors (Hall etof mature T cells in rats, and having ADP-ribosylation
al., 1990; Qin et al., 1993). Interestingly, by the transferactivity). As shown in Figure 1, when CD41 splenic T
of CD41 T cells from anti-CD4 antibody-treated tolerantcell suspensions prepared from normal mice or rats were
mice, naive CD41 T cells in the recipients also graduallydepleted of CD251, RT6.11, CD5high, or CD45RB/RClow
become tolerant and suppressive in the presence of thecells and the remaining CD41 T cells were transferred
donor CD41 T cells and the allograft, potentiating theto syngeneic T cell-deficient or -depleted mice or rats,
tolerant state as long as the graft is present (Qin et al.,the recipients spontaneously developed various organ-
1993). It remains to be determined whether the CD41specific autoimmune diseases (including IDDM, thyroid-
regulatory T cells involved in this ªdominantº trans-itis, and gastritis) and systemic wasting disease in a
plantation tolerance are similar in the phenotype, thefew months. Reconstitution of the eliminated population
function, and the origin to those involved with the naturalinhibited the autoimmune development. Inflammatory
self-tolerance.bowel disease (IBD) can also be induced in T and B
Thymic Production of Regulatory T Cells:cell±deficient SCID mice by transferring similarly treated
Another Key Function of the ThymusT cell suspensions from normal histocompatible mice,
in Maintaining Self-Tolerancealthough it remains to be determined whether this mu-
Does the thymus produce regulatory T cells as a func-rine IBD is due to autoimmunity or heightened immune
tionally mature population or do certain T cells acquireresponses to commensal bacteria in the bowel (Groux
such a regulatory activity in the periphery? Recent stud-and Powrie, 1999).
ies have shown that the normal thymus contains matureThese attempts to search for cell surface markers
CD41 CD82 thymocytes with autoimmune-preventivespecific for the regulatory CD41 T cells are still at an
activity (Itoh et al., 1999; Seddon and Mason, 2000; andearly stage. The profile of the CD41 regulatory T cells
references therein). An attempt to delineate them by cell(such as being CD5high, CD45RB/RClow, RT6.11, or
surface markers (as for peripheral T cells [Figure 1])CD251) is not directly associated with the regulatory
showed that transfer of CD251 cell-depleted maturefunction itself, but may indicate that the cells are in an
CD41 CD82 thymocyte suspensions produced similarªactivated,º ªprimed,º or ªmemoryº state. Nevertheless,
autoimmune diseases in syngeneic T cell±deficientthe results obtained to date show that a subpopulation
mice, and reconstitution of the depleted population pre-of CD41 T cells suppresses the activation and expansion
vented the autoimmune development (Itoh et al., 1999).of potentially pathogenic self-reactive T cells in the nor-
The normal thymus thus seems to be continuously pro-mal immune system, thereby contributing to the mainte-
ducing not only pathogenic self-reactive T cells but alsonance of self-tolerance. Removal or reduction of such
a regulatory CD41 T cell population, which may consti- functionally mature regulatory CD41 T cells controlling
them (Figure 2).tute at most 10% of mature CD41 T cells in the thymus
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The thymus is also able to produce transplantation mice or TGF-receptor-inactivated mice developed vari-
ous autoimmunities (Gorelik and Flavell, 2000; and refer-antigen-specific regulatory CD41 T cells when alloge-
neic thymic epithelial cells are transplanted to athymic ences therein). These findings suggest the possibility
that regulatory CD41 T cells in the T cell±mediated natu-nude mice; T cells that have developed through the
selection process on the engrafted thymic epithelial ral self-tolerance or the transferable transplantation tol-
erance may mediate the suppression by secreting IL-4,cells can suppress naive T cells to respond to allogeneic
skin grafts expressing the same MHC haplotype as the IL-10, or TGF-b. Indeed, administration of neutralizing
antibodies to IL-4 or TGF-b abrogated the in vivo autoim-grafted thymic epithelial cells (Modigliani et al., 1995).
The thymus also appears to be required for establishing mune-preventive or tolerance-inducing activity of CD41
T cells in some models (Seddon and Mason, 1999; Zhaitransplantation tolerance by cyclosporin A or anti-CD4
antibody treatment described above, since removal of and Kupiec-Weglinski, 1999). Recent studies have also
shown that these regulatory CD41 T cells, unlike otherthe thymus before treatment substantially diminishes
the efficacy of inducing tolerance (Zhai and Kupiec- T cells, constitutively express CTLA-4, a costimulatory
molecule in T cell activation, and that T cells stimulatedWeglinski, 1999; and references therein).
Taken together, these results indicate that the thymic via CTLA-4 predominantly secrete TGF-b (Chen et al.,
1998; Solomon et al., 2000). These findings suggest thatselection mechanism may not only delete self-reactive
regulatory CD41 T cells activated through CTLA-4 mightT cells but also give rise to regulatory T cells, presumably
suppress other T cells by secreting TGF-b. On the otherspecific for self-antigens in the case of natural self-
hand, there is substantial data that regulatory CD41 Ttolerance or regulatory T cells specific for allo-antigens
cells control other T cells by a cognate cellular interac-in the case of transplantation tolerance. Elucidation of
tion on APCs (Itoh et al., 1999; and references therein).this mechanism of thymic generation of regulatory T
To further elucidate the role of cytokines in T cell±cells is an important and interesting area of future re-
mediated immunoregulation, it must be determinedsearch.
whether cytokines mediate the suppressive activity itselfCytokines and Regulatory T Cells
of regulatory T cells or whether they influence the devel-Characterization of cytokine-secreting patterns of CD41
opmental milieu of regulatory T cells, since IL-4, IL-10,T cells has revealed in the past decade another aspect
and TGF-b can induce the differentiation of T cells thatof T cell±mediated immunoregulation: the presence of
produce these same cytokines (Groux et al., 1997;CD41 subpopulations secreting distinct patterns of cy-
O'Garra et al., 1997).tokines (Mosmann and Coffman, 1989; O'Garra et al.,
Future Perspective1997). CD41 T cells can be subdivided into Th1 cells,
The phenomena of T cell±mediated suppression in im-which produce IL-2, interferon (IFN)-g and lymphotoxin,
munologic tolerance have been controversial and re-and Th2 cells, which produce IL-4, IL-5, IL-6, and IL-
main an exciting area of active research. An approach13. This segregation well correlates with the effector
from the analysis of autoimmune-preventive activity offunctions of CD41 T cells; i.e., Th1 cells conduct cell-
normal T cells is now revealing a unique regulatory Tmediated immunity by activating macrophages or CD81
cell population dominantly engaged in the maintenancecytotoxic lymphocytes, while Th2 cells help B cells in
of immunologic self-tolerance. Production of such regu-antibody production (Figure 2). Furthermore, these spe-
latory T cells can be another key function of the thymuscific cytokines produced by Th1 and Th2 cells (espe-
in mediating self-tolerance. Recent research has alsocially IFN-g and IL-4, respectively) are also potent cross-
revealed that a part of the suppressive phenomena caninhibitors of the two cell types. Cytokine-secreting
be attributed to immunosuppressive cytokines secretedpattern and cross-inhibition are of great interest from the
by particular types of effector T cells. Therefore, morestandpoint of self-tolerance and autoimmunity. For ex-
than one population of regulatory T cells seem to beample, effector CD41 T cells mediating autoimmune dis-
engaged in the maintenance of self-tolerance and theseease tend to be deviated to Th1 or Th2 type depending
populations function in different waysÐsome are locallyon the type of autoimmune diseaseÐTh1 cells are the
induced as a result of immune responses, while othersmain mediators of organ-specific autoimmune diseases
are naturally produced. Further characterization of the(such as IDDM, thyroiditis, and gastritis), while Th2 cells
function and development of these regulatory T cellsmainly mediate systemic autoimmune diseases (such as
will contribute to our understanding of immunologic self-lupus). Furthermore, control of such cytokine-secreting
tolerance as an acquired process and of the cause andpatterns of self-reactive T cells may be able to inhibit
mechanism of autoimmune disease. Manipulation ofthe development of autoimmune disease or downregu-
regulatory T cells will lead to new strategies for thelate the ongoing autoimmune responses. Indeed, in or-
treatment or prevention of autoimmune disease, trans-gan-specific autoimmune diseases, IDDM in particular,
plant rejection, and cancer.efforts have been made to divert effector T cells from
pathogenic Th1 type to protective Th2 type by adminis-
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